Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Arch Biopartners (ACHFF) Stock Price & Analysis

0 Followers

ACHFF Stock Chart & Stats

$0.62$0.02(2.82%)
At close: 4:00 PM EST
$0.6$0.7$0.8Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.62 - $0.62
52-Week Range
$0.29 - $1.02
Previous Close
$0.60
Volume
N/A
Average Volume (3M)
11.88K
Market Cap
$41.87M
Enterprise Value
$56.39M
Total Cash (Recent Filing)
$2,914
Total Debt (Recent Filing)
$2.73M
Price to Earnings (P/E)
―
Beta
0.34
Next Earnings
Feb 02, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Clinical Pipeline

A clearly defined therapeutic focus can help a small biotechnology company concentrate capital and research resources on a specific unmet medical need. LSALT peptide provides a central development program and a potential path toward clinical differentiation if its intended protective effects are validated.

Narrowing Net Losses

The reduction in annual losses indicates some progress in controlling the company’s cost base and slowing the deterioration of earnings. Although profitability remains unproven, sustained expense discipline could extend operating runway and preserve resources for continued development of its lead program.

Improving Cash Usage

Lower cash consumption than in earlier periods is a constructive operating trend for a development-stage biotechnology company. If maintained, reduced burn could support a longer period of research activity before additional financing is required, even though operations remain dependent on external capital.

Bears Say

No Current Revenue

The absence of current revenue means the company has not yet established a commercialized source of operating income. This leaves financial performance dependent on development progress and future financing rather than customer demand, increasing the time and execution required to reach self-sustaining operations.

Persistent Unprofitability

Repeated losses and negative gross profit indicate that the business has not yet demonstrated sustainable unit economics. Until a product generates commercially viable revenue, ongoing research and corporate costs will continue to pressure earnings and make long-term profitability dependent on successful clinical and commercial development.

Stressed Capitalization

Negative equity, meaningful debt, and a very thin asset base leave limited balance-sheet protection against further operating losses. This capitalization reduces financial flexibility and raises the company’s ongoing funding risk, particularly while revenue is absent and cash generation remains negative.

Arch Biopartners News

ACHFF FAQ

What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was $0.29 and its highest was $1.02 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is $41.87M.
When is Arch Biopartners’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Aug 31, 2026. The company reported -$0.005 earnings per share for the quarter.
Is Arch Biopartners overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -$0.005 in its last earnings report. Following the earnings report the stock price went down -1.37%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in ACHFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology